Lonza | LONN - Cash And Equivalent


Lonza reported CHF719M in Cash and Equivalent for its fiscal semester ending in December of 2025.





Cash And Equivalent Change Date
Akzo Nobel EUR 1.62B 66M Dec/2025
Alcon AG USD 1.58B 80M Mar/2026
Almirall EUR 337.77M 14.83M Dec/2025
AstraZeneca USD 7.56B 1.85B Mar/2026
BASF EUR 2.67B 811M Dec/2025
Bayer EUR 6.67B 774M Dec/2025
Beiersdorf EUR 1.2B 33M Dec/2025
Covestro EUR 648M 44M Dec/2025
Demant DKK 1.33B 188M Dec/2025
Fresenius EUR 1.31B 81M Dec/2025
Fresenius Medical Care EUR 1.24B 343.37M Mar/2026
Geberit CHF 403.6M 4.1M Mar/2025
Genmab DKK 1.72B 46M Dec/2025
Givaudan CHF 603M 3M Jun/2024
GlaxoSmithKline GBP 3.44B 292M Mar/2026
GN Store Nord DKK 1.12B 352M Dec/2025
Hikma Pharmaceutical USD 236M 48M Jun/2025
Johnson Matthey GBP 542M 49M Jun/2024
Merck EUR 2.33B 77M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Philips EUR 2.79B 882M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sika AG CHF 1.87B 1.18B Dec/2022
Solvay EUR 486M 50M Mar/2026
UCB EUR 1.57B 1.14B Dec/2024